Bayesian models and decision algorithms for complex early phase clinical trials
From MaRDI portal
Publication:903294
DOI10.1214/09-STS315zbMath1328.62597arXiv1011.6494WikidataQ37841138 ScholiaQ37841138MaRDI QIDQ903294
Publication date: 5 January 2016
Published in: Statistical Science (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1011.6494
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Medical applications (general) (92C50)
Related Items (6)
A Bayesian stochastic approximation method ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Unnamed Item ⋮ Bayesian Uncertainty Directed Trial Designs ⋮ Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Optimal Designs for Dose-Finding Studies
- Dose-Finding Designs for HIV Studies
- Dose-Finding with Two Agents in Phase I Oncology Trials
- Bayesian Optimal Designs for Phase I Clinical Trials
- A New Dose‐Finding Design for Bivariate Outcomes
- Determining the Effective Sample Size of a Parametric Prior
- Monitoring late-onset toxicities in phase I trials using predicted risks
- Coherence principles in dose-finding studies
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Bayesian Analysis of Binary and Polychotomous Response Data
- Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
This page was built for publication: Bayesian models and decision algorithms for complex early phase clinical trials
